AstraZeneca is launchng a Phase III study (FALCON). It’s a global clinical trial that will involve 450 patients with breast cancer who have not previously been treated with any hormonal therapy.
The Phase III study is designed to evaluate fulvestrant 500 mg. Hypersensitivity reactions, have been reported in association with AstraZeneca’s FASLODEX fulvestrant. AstraZeneca has headquarters and manufacturing operations in northern Delaware.
“The FALCON study is the first Phase III study designed to investigate the potential role of the 500 mg dose of fulvestrant in the treatment of hormone receptor positive advanced breast cancer in patients who have not been previously treated with any hormonal therapy,” said John Robertson, M.D., of the University of Nottingham Royal Derby Hospital.
“The FALCON study has the potential to impact clinical practice concerning endocrine treatment options for women with hormone receptor positive locally advanced or metastatic breast cancer,” said Matthew Ellis, MB BChir PhD, Professor of Medicine, Washington University School of Medicine and Siteman Cancer Center Breast Cancer Program.
Dr. Ellis and Dr. Robertson are the International coordinating investigators for the FALCON Study.
The FALCON study is still opening US clinical trial sites and patient recruitment and enrollment has begun. Additional information about the FALCON clinical trial is available by visiting www.clinicaltrials.gov and searching under the term FALCON.
